RSO-021


Associated tags: Oxidative stress, Biotechnology, Lung, Cancer, Malignant pleural effusion, Drainage, RSO, MPE, Pleural cavity, SOC, Patient, Health, Disease, Research, Malignancy, Mesothelioma, Oncology, Clinical Trials, Pharmaceutical, Pharmaceutical industry

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Multimedia, Mesothelioma, Malignancy, Research, Disease, Patient, Lung, SOC, Pleural cavity, MPE, RSO, Drainage, Malignant pleural effusion, Cancer, Pharmaceutical industry

The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.

Key Points: 
  • The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.
  • (Photo: Dan Ryan)
    Malignant pleural effusion (MPE) is the build up of fluid in the lining membrane (pleura) of the lungs.
  • RSO’s novel, investigational anti-cancer treatment, RSO-021, is administered weekly directly into the pleural space following MPE drainage via an indwelling pleural catheter.
  • “Commencing the Phase 2 portion of our trial presents a major milestone for patients and their caregivers.”